TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Non-Dissection of the Inferior Rectus Sheath on Intraoperative Blood Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Patients must be 18 years or older as well as willing and able to provide informed consent~* Patients undergoing a scheduled or non-scheduled, non-urgent or non-scheduled urgent (delivery within 30 minutes of decision for surgical delivery) Cesarean delivery between \>35 weeks gestational age,~* Patients who are expected to receive a Pfannenstiel incision~* Patients with viable singleton intra-uterine pregnancy~* Patients with fetus in cephalic presentation~Exclusion Criteria:~* - Patients younger than 18 years,~* Patients unable or unwilling to provide informed consent,~* Patients who are illiterate,~* Patients who are non-English speaking or reading,~* Patients who are medical or nursing students at a school affiliated with University Hospital~* Multi-fetal gestations (\>1 intrauterine pregnancy),~* Patients with a BMI \>50 kg/m\^2~* Patients with a suspected placenta accreta or placenta previa~* patients with 2 prior cesarean deliveries~* Patient undergoing emergent cesarean delivery (delivery within 10 minutes of decision for surgical delivery)~* Patients who will require a vertical skin incision, Maylard or Cherney incisions~* Patients with a history of significant pelvic adhesive disease, as determined by prior operative reports~* Patients with fetus in non-cephalic presentation~* Patients with pre-gestational or gestational diabetes mellitus~* Patients with estimated fetal weight \>5000 grams~* Patients with estimated fetal weight \<10% for gestational age~* Patients with who require general anesthetic~* Patients who are on chronic pain medication~* Patients with a history of drug abuse

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): Patients will undergo non-dissection of the inferior rectus sheath at time of primary cesarean delivery
- Control (Type: PLACEBO_COMPARATOR): Patients will undergo standard practice which is dissection of the superior and inferior rectus sheath at time of cesarean delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Conversational Hypnosis in Women Undergoing Imaging for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥ 18 years old~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Patient undergoing for a preoperative breast assessment~* Patient must be affiliated to a social security system~* Ability to provide an informed written consent form~Exclusion Criteria:~* Patients diagnosed with major hearing loss~* Patients with schizophrenia~* Patients do not understand the French language~* Pregnant or breast feeding females~* Refusal of the patient to participate in the study~* Persons deprived of liberty or under supervision

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard care (Type: ACTIVE_COMPARATOR): None
- standard care+conversational hypnosis (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Alone to Insulin With Metformin to Treat Gestational Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to read and write English and/or Spanish and give written consent~* Diagnosis of GDM, defined as an abnormal glucose tolerance test performed after 12 weeks gestation using 1 of the 2 criteria below:~* 50 gram 1 hour oral diabetes screening testing yielding a result of \> 200 mg/dL~* A 100 gram 3 hour oral glucose tolerance testing yielding \>2 abnormal values (normal values defined as fasting blood glucose \< 95, 1 hour \< 180, 2 hour \< 155 and 3 hour \< 140)~* Singleton gestation~* Gestational age between 12 and 34 weeks and 6 days determined by last menstrual period (LMP) confirmed by ultrasound using criteria set forth by the ACOG (Committee on Obstetric Practice). If LMP is unknown then gestational age must be set by ultrasound prior to 20 weeks gestation.~Exclusion Criteria:~* Pre-existing DM either by diagnosis preceding pregnancy or hemoglobin A1c \>6.5 collected during the current pregnancy~* Uncontrolled chronic hypertension, as this may alter maternal and perinatal outcomes measured.~* Multiple gestations~* Major fetal anomalies anticipated to require NICU admission~* Contraindication to metformin (allergy, history of lactic acidosis, pre-existing renal disease (Cr \>1.5 mg/dL), active liver disease, current alcohol abuse).~* Vitamin B12 deficiency, as metformin reduces intestinal absorption of vitamin B12~* Medications known to effect glucose metabolism other than insulin and metformin as this may mask any effect between the two treatments.~* Known inability to tolerate metformin.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- insulin (Type: ACTIVE_COMPARATOR): None
- insulin and metformin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Female or male sex.~2. Diagnosis (confirmed by clinical review) of A/MBC, defined as breast cancer at stage IIIB, stage IIIC, stage IV or identified as having distant metastasis.~3. Age ≥18 years at A/MBC diagnosis.~4. Initiated a CDK4/6i in combination with an AI as initial endocrine-based therapy after A/MBC diagnosis on or after 2/3/2015 and before 4/1/2019.~   •Note that the date of the start of the inclusion period reflects the month that the first CDK4/6i (ie, Palbociclib) received U.S. FDA approval.~5. Evidence of ER or PR positive disease, or absence of any indication of ER and PR negative disease closest to A/MBC diagnosis (ie, patients are eligible without affirmative indication of ER/PR+ status as long as ER/PR- indication is not present).~6. Evidence of HER2 negative disease, or absence of any indication of HER2 positive disease closest to A/MBC diagnosis (ie, patients are eligible without affirmative indication of HER2- status as long as HER2+ indication is not present).~Exclusion Criteria:~1. Enrollment in an interventional clinical trial for A/MBC during the study observation period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breast Cancer Patients (Type: None): HR + /HER2- Advanced/Metastatic Breast Cancer patients in U.S.A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria: Acute pyelonephritis without severity symptoms with a positive urine culture for ESBL-producing E. coli (cefoxitin-sensitive); antibiotic treatment should have been prescribed before inclusion for the empirical treatment of pyelonephritis, providing it is not active in vitro against ESBL-producing E. coli strain.~* Presenting at least a functional sign of urinary infection (dysuria, cloudy urine, pain on urination, pelvic or lumbar pain)~* Temperature \>38 ° or \< 36° during the infectious episode~* Imaging of the urinary ways realized within (echography) 72 hours preceding the inclusion.~Exclusion Criteria:~* Pregnant women~* β-lactam allergy;~* antimicrobial therapy active in vitro against ESBL-producing E.coli pyelonephritis instituted prior to enrolment;~* life expectancy \<30 days;~* creatinine clearance \<30 ml/min;~* patient under guardianship or without healthcare coverage.~* Sign of sepsis severe or septic shock~* Major cognitive confusions~* Patients having refused to give her consent form in writing~* Not membership in a national insurance scheme or in the Universal Health Coverage (CMU).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cefoxitin (Type: EXPERIMENTAL): this study is centered on women with pyelonephritis without severity symptoms due to ESBL-producing E. coli.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a living or deceased donor kidney transplant~* Failed current standard of care for late antibody-mediated rejection~* Persistent de novo donor specific antibody and a concurrent biopsy with histologic evidence of acute antibody-mediated inflammation~* Adults with reproductive potential must agree to use approved methods of birth control while in the study~Exclusion Criteria:~* Leukopenia (WBC) \< 3.0 x 109/L~* Creatinine Clearance less than or equal to 25 ml/min/1.73m2~* HCV or HBV positive~* BKV or CMV viremia assessed by PCR~* Any active infection~* Use of other investigational drugs within 4 weeks of study~* Pregnancy/breast feeding/unwilling or unable to take birth control~* Active malignancy~* de novo DSA occurring equal to or greater than15 years after kidney transplant~* Screening biopsy with equal to or greater than cg2 on Banff criteria~* Cumulative/lifetime dose of cyclophosphamide, including anticipated total study dose (calculated according to Creatinine Clearance and mg/kg/day) equal to or greater than 36 g.~* Any condition that, in the opinion of the investigator, would pose risk to the subject's safe participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide (Type: EXPERIMENTAL): Cyclophosphamide 1.5 mg/kg orally daily for 180 days (26 weeks) adjusted for renal function.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ankle Equinus Contracture Treated With Dynamic Splinting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous Diagnosis Diabetes Mellitus~* Reduced flexibility in AROM of extension in the ankle~* Less than 10º Maximal, Active Dorsiflexion, while upright~* Impaired gait pattern~Exclusion Criteria:~* Previous surgical treatment for this pathology~* Previous surgery of the Achilles tendon or triceps surae~* Current treatment with corticosteroids~* Current treatment with Botulinium Toxin-A (Botox), lower extremity~* Current treatment Fluoroquinolones (antibiotic medication)~* Current use of muscle relaxant medications~* Fibromyalgia~* Stroke, CVA, Brain Injury, Spinal Cord Injury, or any neural pathology causing plasticity or hypertonicity~* Current participation in manual, physical therapy~* Treatment with electrical stimulation assisting ambulation (i.e. Bioness, WalkAide, Parastep, etc.)~* Preexisting open sores on foot or leg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Patients in the control group will be treated with the current standard of care including shoe modification and home stretching exercises.
- Experimental (Type: EXPERIMENTAL): Patients assigned to the experimental group will receive the current standard of care as well as the Ankle Dorsiflexion Dynasplint.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients no younger than 18 years of age~* Recently diagnosed pulmonary hypertension (defined by RV systolic pressure of ≥ 40 mmHg as measured by echocardiography), going for invasive hemodynamic assessment for pulmonary hypertension~* Normal left ventricular function defined as a left ventricular ejection fraction (LVEF) greater than or equal to 50%~Exclusion Criteria:~* Heart failure (LVEF \< 50%, diastolic dysfunction \> stage 1, history or symptoms of left heart failure) - Group II pulmonary hypertension~* 2+ or higher MR or AI~* Inadequate echocardiographic windows~* Pregnancy~* Systolic blood pressure ≤ 90 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iloprost and nitric oxide administration (Type: EXPERIMENTAL): Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~- Moderate to severe pain due to non-traumatic vertebral fracture associated with osteoporosis.~Exclusion criteria:~* Mild pain score on the Pain Intensity-Numeric Rating Scale \[PI-NRS\] at screening and randomization visits;~* Narcotic addiction;~* Post-fracture vertebral instability;~* Unwillingness to use study-defined rescue analgesia exclusively.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- REGN475/SAR164877 (Type: EXPERIMENTAL): REGN475/SAR164877, single injection, dose depending on the participant's body weight
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for REGN475/SAR164877), single injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject has received mechanical ventilation for at least 48h at the time of the randomisation OR at least 2 of the following signs or symptoms presenting within 24 hours prior to randomization: New onset of cough or worsening of baseline cough and/or dyspnea, tachypnea and/or hypoxemia and/or new onset of sputum or suctioned respiratory secretion characterized by purulent appearance indicative of bacterial infection or a worsening in character of purulent appearance~* Acute Physiology and Chronic Health Evaluation (APACHE) of 8 to 25, inclusive, within 24h prior to randomization~* Presence of new or progressive infiltrate on chest X-ray~* Presence of clinical criteria consistent with Pneumonia~* Strong clinical suspicion of pneumonia due to P. aeruginosa~Key Exclusion Criteria:~* Known or suspected community-acquired bacterial pneumonia or viral, fungal, or parasitic pneumonia~* known hypersensitivity to any component of ertapenem, meropenem or to other drugs in the same class or demonstrated anaphylactic reactions to beta-lactams or a history of allergic reactions to any of the penicillins, cephalosporins, or β-lactamase inhibitors~* Severe liver or renal impairment~* Expected survival \< 72 hours~* Evidence from an available surveillance culture of co infection with ertapenem , meropenem or piperacillin tazobactam resistant Gram negative pathogen(s)~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Murepavadin (Type: EXPERIMENTAL): Murepavadin + ertapenem
- Anti-pseudomonal antibiotic (Type: ACTIVE_COMPARATOR): One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Role of Pregabalin in Reducing Opioid Requirement in Spinal Fusion Surgeries of Two or More Vertebrae

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age : \> 18 years old~* Fusion of \> two vertebrae~* Capacity to provide consent~* ASA I-IV~* Ability to swallow capsules~Exclusion Criteria:~* Plan of care includes intubated ICU admission post-op~* Allergy to gabapentin or pregabalin~* Two week prior use of pregabalin~* Significant renal dysfunction (creatinine level \>2)~* Severe cardiovascular disease~* History of frequent headaches or dizziness~* Significant hepatic dysfunction (LFT's \> 4 times the normal ranges)~* Active usage of alcohol or illicit substances three days prior to surgery~* History of seizure disorders~* Taking medication for anxiety, antiseizure, and psychiatric diagnoses~* Re-operation patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pregabalin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CDI is confirmed by clinical symptoms and rapid CDI test~* Subject has not been treated with medication for CDI within the last 10 days~* Subject is:~  * receiving immunosuppressive therapy (chemotherapy) or is undergoing a stem cell transplant procedure (defined as the time period from the start of conditioning prior to transplant until 6 months after infusion of stem cells) for a hematological malignancy; or~ * receiving immunosuppressive therapy (chemotherapy) for a solid tumor malignancy or following solid organ transplantation; or~ * being treated with immunosuppressive and /or anti-TNF therapy for an auto-immune disease~* Any woman of childbearing potential requires negative serum or urine pregnancy test before entry to the study~* Male and female subjects that are sexually active must agree to practice effective birth control during the study and for 30 days after the end of the study~Exclusion Criteria:~* The subject has experienced more than one previous episode of CDI within the 3 months prior to study inclusion~* Taking or requiring to be treated with prohibited medications~* Unable to take oral study medication~* Female patients that are pregnant, intend to become pregnant or are breastfeeding~* History of ulcerative colitis or Crohn's disease~* History or diagnosis of toxic megacolon or pseudomembranous colitis~* Hypersensitivity to fidaxomicin or any of its components~* Hypersensitivity to vancomycin or any of its components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fidaxomicin (Type: EXPERIMENTAL): Fidaxomicin with alternating matching placebo
- Vancomycin (Type: ACTIVE_COMPARATOR): Participants received 4 doses (1 dose every 6 hours) of oral vancomycin hydrochloride each day for the duration of the 10-day treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues